<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A682D253-DEE6-4EE1-89B0-21F1351C632C"><gtr:id>A682D253-DEE6-4EE1-89B0-21F1351C632C</gtr:id><gtr:name>National Cancer Institute (NCI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0FAD414C-F1ED-47A8-96CE-8B55D05CBB74"><gtr:id>0FAD414C-F1ED-47A8-96CE-8B55D05CBB74</gtr:id><gtr:name>SFCE/GSF-GETO</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22C15C82-7C78-474C-A946-E96D7705AFFF"><gtr:id>22C15C82-7C78-474C-A946-E96D7705AFFF</gtr:id><gtr:name>Scandinavian Sarcoma Group (SSG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89C3FBD6-D155-467E-B372-0CDAD4F56AA0"><gtr:id>89C3FBD6-D155-467E-B372-0CDAD4F56AA0</gtr:id><gtr:name>Sarcoma Alliance for Research through Collaboration (SARC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B9A70B68-57E0-4980-8B78-35EC3EF12BB1"><gtr:id>B9A70B68-57E0-4980-8B78-35EC3EF12BB1</gtr:id><gtr:name>Cooperative Osteosarcoma Study Group (COSS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/051356B5-A429-4851-8AAA-E43372AA6586"><gtr:id>051356B5-A429-4851-8AAA-E43372AA6586</gtr:id><gtr:name>Australasian Sarcoma Study Group (ASSG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6E70EC85-0C2B-44B5-8270-6EE8B87AAD37"><gtr:id>6E70EC85-0C2B-44B5-8270-6EE8B87AAD37</gtr:id><gtr:name>Japanese Clinical Oncology Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7E30C50D-27E9-4D88-A579-5011EBD4A668"><gtr:id>7E30C50D-27E9-4D88-A579-5011EBD4A668</gtr:id><gtr:name>Spanish Group for Research on Sarcomas (GEIS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E00B55DD-8384-4AFE-8BD6-B5A47DD6CBC6"><gtr:id>E00B55DD-8384-4AFE-8BD6-B5A47DD6CBC6</gtr:id><gtr:name>European and American Osteosarcoma Study Group (EURAMOS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E6612F94-7C16-4F91-9013-7A2FE5DD03A2"><gtr:id>E6612F94-7C16-4F91-9013-7A2FE5DD03A2</gtr:id><gtr:name>ISG Italian Sarcoma Group</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A682D253-DEE6-4EE1-89B0-21F1351C632C"><gtr:id>A682D253-DEE6-4EE1-89B0-21F1351C632C</gtr:id><gtr:name>National Cancer Institute (NCI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0FAD414C-F1ED-47A8-96CE-8B55D05CBB74"><gtr:id>0FAD414C-F1ED-47A8-96CE-8B55D05CBB74</gtr:id><gtr:name>SFCE/GSF-GETO</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22C15C82-7C78-474C-A946-E96D7705AFFF"><gtr:id>22C15C82-7C78-474C-A946-E96D7705AFFF</gtr:id><gtr:name>Scandinavian Sarcoma Group (SSG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89C3FBD6-D155-467E-B372-0CDAD4F56AA0"><gtr:id>89C3FBD6-D155-467E-B372-0CDAD4F56AA0</gtr:id><gtr:name>Sarcoma Alliance for Research through Collaboration (SARC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B9A70B68-57E0-4980-8B78-35EC3EF12BB1"><gtr:id>B9A70B68-57E0-4980-8B78-35EC3EF12BB1</gtr:id><gtr:name>Cooperative Osteosarcoma Study Group (COSS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/051356B5-A429-4851-8AAA-E43372AA6586"><gtr:id>051356B5-A429-4851-8AAA-E43372AA6586</gtr:id><gtr:name>Australasian Sarcoma Study Group (ASSG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6E70EC85-0C2B-44B5-8270-6EE8B87AAD37"><gtr:id>6E70EC85-0C2B-44B5-8270-6EE8B87AAD37</gtr:id><gtr:name>Japanese Clinical Oncology Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7E30C50D-27E9-4D88-A579-5011EBD4A668"><gtr:id>7E30C50D-27E9-4D88-A579-5011EBD4A668</gtr:id><gtr:name>Spanish Group for Research on Sarcomas (GEIS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E00B55DD-8384-4AFE-8BD6-B5A47DD6CBC6"><gtr:id>E00B55DD-8384-4AFE-8BD6-B5A47DD6CBC6</gtr:id><gtr:name>European and American Osteosarcoma Study Group (EURAMOS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E6612F94-7C16-4F91-9013-7A2FE5DD03A2"><gtr:id>E6612F94-7C16-4F91-9013-7A2FE5DD03A2</gtr:id><gtr:name>ISG Italian Sarcoma Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A415FBFD-F657-4BE1-B8B7-33C8B25DA5E9"><gtr:id>A415FBFD-F657-4BE1-B8B7-33C8B25DA5E9</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Sydes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C2ADAD1C-4A0B-4FFE-BEC7-6C6CAF45BB60"><gtr:id>C2ADAD1C-4A0B-4FFE-BEC7-6C6CAF45BB60</gtr:id><gtr:firstName>Max</gtr:firstName><gtr:surname>Parmar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122861384"><gtr:id>C4828726-0D4F-4F26-8F88-4F28130CD7FD</gtr:id><gtr:title>Clinical trials in osteosarcoma and soft tissue sarcoma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122861384</gtr:grantReference><gtr:abstractText>This programme is trying to find improved ways to approach the treatment with sarcoma, in particular bone cancer (osteosarcoma).||The mainstay of treatment is surgery to remove the tumour. Outcomes for patients improved greatly when chemotherapy (drug treatment) before and after surgery became part of standard care in the 1970s. Through a collaborative research group (the European Osteosarcoma Intergroup), the MRC Clinical Trials Unit, has run four trials of chemotherapy. In the first three studies (BO02, BO03, BO06), the standard regimen was the same and involved two drugs: cisplatin and doxorubicin (adriamycin). The trials showed that the ways in which we have tried to improve chemotherapy with increased dose, increased numbers of drugs and drugs given more intensely were not reliably shown to be better than the standard treatment. In the current study, EURAMOS-1, the standard treatment is a three-drug approach that has been standard in North America.||For patients who respond well at first to chemotherapy, the research arm of EURAMOS-1 is maintenance therapy (2 years of monthly treatment with interferon, a biological drug) For patients who do not respond so well, the research arm of is more intensive treatment with more drugs. More than 1000 patients across Europe and in North America have joined the trial since Summer 2005, making it the largest single study in osteosarcoma. Around 2000 consenting patients will be recruited. Other groups are interested to use these data for further analyses and this is being discussed.</gtr:abstractText><gtr:technicalSummary>Although rare in absolute terms, osteosarcoma is the most common form of primary bone cancer with an incidence of 150-250 new cases per annum in the UK. Osteosarcoma can occur at any age, but is most commonly found in teenagers and young adults, and is slightly more common in males. Any bone in the body can be affected but the commonest sites are the arms or legs, particularly around the knee joint. Prior to the introduction of adjuvant chemotherapy, 5-year survival for patients with operable osteosarcoma, treated using amputation alone, was less than 20%. The introduction in the mid-1970s of adjuvant and neo-adjuvant chemotherapy using intensive multi-agent schedules has led to 5-year survival in excess of 50%. As neo-adjuvant chemotherapy has increased in usage, limb salvage has become the mainstay of surgical management.||In order to conduct meaningful clinical trials in this rare disease, international collaboration is essential. The MRC performs trials with other leading research groups under the auspices of the European Osteosarcoma Intergroup and the EURAMOS collaboration. In two previous randomised trials, BO02 and BO03, it has been shown that lengthy, multi-agent chemotherapy regimens offer no survival benefit when compared with a shorter two-drug regimen consisting of cisplatin and doxorubicin. The trial MRC BO06 (EORTC 80931) trial, published in January 2007, investigated whether survival could be improved by increasing the intensity of the now standard two-drug regimen using granulocyte colony stimulating factor (G-CSF), a haemopoietic growth factor; no good evidence of an advantage was found for the more intensive arm.||In October 2005, the EURAMOS-1 trial opened to recruitment in the UK, where EURAMOS is the EUropean and AMerican Osteosarcoma Study group. EURAMOS is a collaboration between the European Osteosarcoma Intergroup and similar research bodies in central Europe, Scandinavia and North America. Together these groups can recruit more patients and so more quickly address the most important questions. In EURAMOS-1, all patients receive the same pre-operative chemotherapy followed by surgery as per usual practice. After surgery, patients who have had a poorer response to pre-operative chemotherapy are randomised to continue with the same treatment or to receive more intensive treatment; patients who have had a better response to pre-operative chemotherapy continue on the pre-operative chemotherapy regimen but are randomised to receive or not receive long-term maintenance therapy. Recruitment to the trial in terms of registrations has been very good. The trial is supported by the European Science Foundations EUROCORES-ECT programme, funded in the UK by MRC and Cancer Research UK and sponsored in Europe by MRC with delegated responsibilities set out in the EURAMOS Framework Agreement. MRC CTU is the Data Centre for the European Osteosarcoma Intergroup and the Coordinating Data Centre for the trial, overall. The planned associated biology studies are now being initiated.||The MRC CTU Cancer Group also conducts associated research in osteosarcoma using the wealth of clinical information collected for previous trials. Long-term follow-up data from BO02 and BO03 were presented in 2000 that suggest that relapses in patients free of disease for five years occur in less than 5% of patients and a paper in 2006 looked at baseline data for late-relapsing patients across a number of osteosarcoma trials. The relationship between received dose intensity and outcome for two-drug therapy was described in a paper published in 2000; dose intensity was found to have no influence on survival or progression-free survival. Long-term cohort data on BO02, BO03 and BO06 have been analysed together and papers are in the late stages of development.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1355963</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Australasian Sarcoma Study Group (ASSG)</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Australian-led group for age cohorts</gtr:description><gtr:id>4456CC6B-1559-4E7F-97A5-FBD2802A9085</gtr:id><gtr:impact>Conference presentations made late in 2010. A manuscript is in preparation and will be submitted for publication in late 2011/early 2012.</gtr:impact><gtr:outcomeId>Vi1k44gq75c-1</gtr:outcomeId><gtr:partnerContribution>Led research; we provided data and comments in design and interpretation</gtr:partnerContribution><gtr:piContribution>Provision of data from BO02, BO03 and BO06 trials. Input to design and interpretation of data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SFCE/GSF-GETO</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EURAMOS Strategy Group</gtr:description><gtr:id>B0F9516F-FD83-428E-9860-24FFC1C1B3F3</gtr:id><gtr:impact>Two detailed meeting reports on the 2010 and 2012 have been produced for the European Science Foundation and two consensus papers for publication are in development. 
Further combined guidelines and prioritisation papers are in development (Nov-2012)</gtr:impact><gtr:outcomeId>aVJ4TH57b2b-6</gtr:outcomeId><gtr:partnerContribution>Intellectual input into regular group meetings and consensus conferences.</gtr:partnerContribution><gtr:piContribution>Collaboration of global osteosarcoma clinical research groups to develop a co-ordinated strategy for research in this rare cancer. Contribution from the MRC CTU has been to organise two consensus conferences aimed at developing future trial concepts (Future Clinical Trials for Adjuvant Treatment of Osteosarcoma - Prioritising the Questions, London 2010) and defining standard trial procedures (2nd International Meeting on Future Clinical Trials for the Adjuvant Treatment of Osteosarcoma: Creating a Strategic Consensus, London 2012). The most recent meeting was Oct-2014 in Berlin which MRC CTU attended and minuted.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Soft Tissue and Bone Sarcoma Sub Group</gtr:department><gtr:description>EURAMOS Strategy Group</gtr:description><gtr:id>22F378DE-E226-4A13-88F0-ACB782B08C29</gtr:id><gtr:impact>Two detailed meeting reports on the 2010 and 2012 have been produced for the European Science Foundation and two consensus papers for publication are in development. 
Further combined guidelines and prioritisation papers are in development (Nov-2012)</gtr:impact><gtr:outcomeId>aVJ4TH57b2b-4</gtr:outcomeId><gtr:partnerContribution>Intellectual input into regular group meetings and consensus conferences.</gtr:partnerContribution><gtr:piContribution>Collaboration of global osteosarcoma clinical research groups to develop a co-ordinated strategy for research in this rare cancer. Contribution from the MRC CTU has been to organise two consensus conferences aimed at developing future trial concepts (Future Clinical Trials for Adjuvant Treatment of Osteosarcoma - Prioritising the Questions, London 2010) and defining standard trial procedures (2nd International Meeting on Future Clinical Trials for the Adjuvant Treatment of Osteosarcoma: Creating a Strategic Consensus, London 2012). The most recent meeting was Oct-2014 in Berlin which MRC CTU attended and minuted.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ISG Italian Sarcoma Group</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>EURAMOS Strategy Group</gtr:description><gtr:id>32881B96-B560-478F-80C4-9F4222525E49</gtr:id><gtr:impact>Two detailed meeting reports on the 2010 and 2012 have been produced for the European Science Foundation and two consensus papers for publication are in development. 
Further combined guidelines and prioritisation papers are in development (Nov-2012)</gtr:impact><gtr:outcomeId>aVJ4TH57b2b-5</gtr:outcomeId><gtr:partnerContribution>Intellectual input into regular group meetings and consensus conferences.</gtr:partnerContribution><gtr:piContribution>Collaboration of global osteosarcoma clinical research groups to develop a co-ordinated strategy for research in this rare cancer. Contribution from the MRC CTU has been to organise two consensus conferences aimed at developing future trial concepts (Future Clinical Trials for Adjuvant Treatment of Osteosarcoma - Prioritising the Questions, London 2010) and defining standard trial procedures (2nd International Meeting on Future Clinical Trials for the Adjuvant Treatment of Osteosarcoma: Creating a Strategic Consensus, London 2012). The most recent meeting was Oct-2014 in Berlin which MRC CTU attended and minuted.</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Japanese Clinical Oncology Group</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>EURAMOS Strategy Group</gtr:description><gtr:id>41E152C7-099D-47A3-92C9-9792E22D0D37</gtr:id><gtr:impact>Two detailed meeting reports on the 2010 and 2012 have been produced for the European Science Foundation and two consensus papers for publication are in development. 
Further combined guidelines and prioritisation papers are in development (Nov-2012)</gtr:impact><gtr:outcomeId>aVJ4TH57b2b-10</gtr:outcomeId><gtr:partnerContribution>Intellectual input into regular group meetings and consensus conferences.</gtr:partnerContribution><gtr:piContribution>Collaboration of global osteosarcoma clinical research groups to develop a co-ordinated strategy for research in this rare cancer. Contribution from the MRC CTU has been to organise two consensus conferences aimed at developing future trial concepts (Future Clinical Trials for Adjuvant Treatment of Osteosarcoma - Prioritising the Questions, London 2010) and defining standard trial procedures (2nd International Meeting on Future Clinical Trials for the Adjuvant Treatment of Osteosarcoma: Creating a Strategic Consensus, London 2012). The most recent meeting was Oct-2014 in Berlin which MRC CTU attended and minuted.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Australasian Sarcoma Study Group (ASSG)</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>EURAMOS Strategy Group</gtr:description><gtr:id>C4E6C8D4-8850-4486-A09E-6C6099B94CAA</gtr:id><gtr:impact>Two detailed meeting reports on the 2010 and 2012 have been produced for the European Science Foundation and two consensus papers for publication are in development. 
Further combined guidelines and prioritisation papers are in development (Nov-2012)</gtr:impact><gtr:outcomeId>aVJ4TH57b2b-7</gtr:outcomeId><gtr:partnerContribution>Intellectual input into regular group meetings and consensus conferences.</gtr:partnerContribution><gtr:piContribution>Collaboration of global osteosarcoma clinical research groups to develop a co-ordinated strategy for research in this rare cancer. Contribution from the MRC CTU has been to organise two consensus conferences aimed at developing future trial concepts (Future Clinical Trials for Adjuvant Treatment of Osteosarcoma - Prioritising the Questions, London 2010) and defining standard trial procedures (2nd International Meeting on Future Clinical Trials for the Adjuvant Treatment of Osteosarcoma: Creating a Strategic Consensus, London 2012). The most recent meeting was Oct-2014 in Berlin which MRC CTU attended and minuted.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Institute (NCI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Children's Oncology Group (COG)</gtr:department><gtr:description>EURAMOS Strategy Group</gtr:description><gtr:id>CAC03500-D205-4ECB-B1E5-8AF8F33D646D</gtr:id><gtr:impact>Two detailed meeting reports on the 2010 and 2012 have been produced for the European Science Foundation and two consensus papers for publication are in development. 
Further combined guidelines and prioritisation papers are in development (Nov-2012)</gtr:impact><gtr:outcomeId>aVJ4TH57b2b-2</gtr:outcomeId><gtr:partnerContribution>Intellectual input into regular group meetings and consensus conferences.</gtr:partnerContribution><gtr:piContribution>Collaboration of global osteosarcoma clinical research groups to develop a co-ordinated strategy for research in this rare cancer. Contribution from the MRC CTU has been to organise two consensus conferences aimed at developing future trial concepts (Future Clinical Trials for Adjuvant Treatment of Osteosarcoma - Prioritising the Questions, London 2010) and defining standard trial procedures (2nd International Meeting on Future Clinical Trials for the Adjuvant Treatment of Osteosarcoma: Creating a Strategic Consensus, London 2012). The most recent meeting was Oct-2014 in Berlin which MRC CTU attended and minuted.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sarcoma Alliance for Research through Collaboration (SARC)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>EURAMOS Strategy Group</gtr:description><gtr:id>E932A39F-691D-422C-9284-015EF2034034</gtr:id><gtr:impact>Two detailed meeting reports on the 2010 and 2012 have been produced for the European Science Foundation and two consensus papers for publication are in development. 
Further combined guidelines and prioritisation papers are in development (Nov-2012)</gtr:impact><gtr:outcomeId>aVJ4TH57b2b-9</gtr:outcomeId><gtr:partnerContribution>Intellectual input into regular group meetings and consensus conferences.</gtr:partnerContribution><gtr:piContribution>Collaboration of global osteosarcoma clinical research groups to develop a co-ordinated strategy for research in this rare cancer. Contribution from the MRC CTU has been to organise two consensus conferences aimed at developing future trial concepts (Future Clinical Trials for Adjuvant Treatment of Osteosarcoma - Prioritising the Questions, London 2010) and defining standard trial procedures (2nd International Meeting on Future Clinical Trials for the Adjuvant Treatment of Osteosarcoma: Creating a Strategic Consensus, London 2012). The most recent meeting was Oct-2014 in Berlin which MRC CTU attended and minuted.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scandinavian Sarcoma Group (SSG)</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>EURAMOS Strategy Group</gtr:description><gtr:id>471BF208-A9AF-4A7F-85E6-E5E3DA3AFA1F</gtr:id><gtr:impact>Two detailed meeting reports on the 2010 and 2012 have been produced for the European Science Foundation and two consensus papers for publication are in development. 
Further combined guidelines and prioritisation papers are in development (Nov-2012)</gtr:impact><gtr:outcomeId>aVJ4TH57b2b-3</gtr:outcomeId><gtr:partnerContribution>Intellectual input into regular group meetings and consensus conferences.</gtr:partnerContribution><gtr:piContribution>Collaboration of global osteosarcoma clinical research groups to develop a co-ordinated strategy for research in this rare cancer. Contribution from the MRC CTU has been to organise two consensus conferences aimed at developing future trial concepts (Future Clinical Trials for Adjuvant Treatment of Osteosarcoma - Prioritising the Questions, London 2010) and defining standard trial procedures (2nd International Meeting on Future Clinical Trials for the Adjuvant Treatment of Osteosarcoma: Creating a Strategic Consensus, London 2012). The most recent meeting was Oct-2014 in Berlin which MRC CTU attended and minuted.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cooperative Osteosarcoma Study Group (COSS)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>EURAMOS Strategy Group</gtr:description><gtr:id>71A47DB6-CE64-4B3E-98EE-9C2BE097B882</gtr:id><gtr:impact>Two detailed meeting reports on the 2010 and 2012 have been produced for the European Science Foundation and two consensus papers for publication are in development. 
Further combined guidelines and prioritisation papers are in development (Nov-2012)</gtr:impact><gtr:outcomeId>aVJ4TH57b2b-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input into regular group meetings and consensus conferences.</gtr:partnerContribution><gtr:piContribution>Collaboration of global osteosarcoma clinical research groups to develop a co-ordinated strategy for research in this rare cancer. Contribution from the MRC CTU has been to organise two consensus conferences aimed at developing future trial concepts (Future Clinical Trials for Adjuvant Treatment of Osteosarcoma - Prioritising the Questions, London 2010) and defining standard trial procedures (2nd International Meeting on Future Clinical Trials for the Adjuvant Treatment of Osteosarcoma: Creating a Strategic Consensus, London 2012). The most recent meeting was Oct-2014 in Berlin which MRC CTU attended and minuted.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European and American Osteosarcoma Study Group (EURAMOS)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>European Osteosarcoma Group (EOI)</gtr:department><gtr:description>European Osteosarcoma Intergroup</gtr:description><gtr:id>6EB4E468-36CD-43EB-B41A-C329B9221666</gtr:id><gtr:impact>Recent publications: 22036088, 16426841, 17227995, 21216138 and 22015453. Previous publications and trials (not listed). Development of EURAMOS collaboration (part of same program but listed under G0400248)</gtr:impact><gtr:outcomeId>4D7C64CE839-1</gtr:outcomeId><gtr:partnerContribution>Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Work with the EOI led to the EURAMOS collaboration (see grant G0400248)</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of trial data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Spanish Group for Research on Sarcomas (GEIS)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>EURAMOS Strategy Group</gtr:description><gtr:id>19235AA0-1E22-4CE2-9253-8E3AAE86A8BD</gtr:id><gtr:impact>Two detailed meeting reports on the 2010 and 2012 have been produced for the European Science Foundation and two consensus papers for publication are in development. 
Further combined guidelines and prioritisation papers are in development (Nov-2012)</gtr:impact><gtr:outcomeId>aVJ4TH57b2b-8</gtr:outcomeId><gtr:partnerContribution>Intellectual input into regular group meetings and consensus conferences.</gtr:partnerContribution><gtr:piContribution>Collaboration of global osteosarcoma clinical research groups to develop a co-ordinated strategy for research in this rare cancer. Contribution from the MRC CTU has been to organise two consensus conferences aimed at developing future trial concepts (Future Clinical Trials for Adjuvant Treatment of Osteosarcoma - Prioritising the Questions, London 2010) and defining standard trial procedures (2nd International Meeting on Future Clinical Trials for the Adjuvant Treatment of Osteosarcoma: Creating a Strategic Consensus, London 2012). The most recent meeting was Oct-2014 in Berlin which MRC CTU attended and minuted.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation of the EURAMOS-1 Poor Responders randomisation first results</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B07B0A06-87B2-4880-B45B-DCFB9AF44AC6</gtr:id><gtr:impact>First results of this important comparison were presented at international conferences. More presentations will follow in China, UK and Germany, at least, given by the lead investigators. A paper is in development.

MAP chemotherapy will the international standard of care.</gtr:impact><gtr:outcomeId>5458ef6c015bf5.13082855</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.ctos.org/PDFs/CTOS%202014%20AM%20FP%20complete%20rfs%20electronic.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BO06 results to public</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EB5F06C4-E0D2-4FFD-953B-50A5FBFA46F1</gtr:id><gtr:impact>Results of the BO06 trial were summarised in a patient newsletter

Information for patients</gtr:impact><gtr:outcomeId>478014AFFE2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Science Foundation funding for EURAMOS-1 --&amp;gt; U122861384 (one of many co-funders for many destinations --&amp;gt; approx UK total shown)</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>European Science Foundation (ESF)</gtr:fundingOrg><gtr:fundingRef>CRUK/06/019 [A3804] - Cancer Research UK seems to consider this as one with the original grant. We did not expect this.</gtr:fundingRef><gtr:id>F4C500D5-C2F9-4BC7-AF0D-2CF6563F0F57</gtr:id><gtr:outcomeId>ALYurbETapB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2005-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK / CTAAC funding for EURAMOS-1 --&amp;gt; U122861384 (one of many co-funders for many destinations --&amp;gt; approx UK total shown)</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>E95E0553-C71C-4867-AC6B-D949D9EB785F</gtr:id><gtr:outcomeId>Wy6Jp3NX5T30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2005-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC trial funding grant for EURAMOS-1 --&amp;gt; U122861384 (one of many co-funders for many destinations --&amp;gt; approx UK total shown)</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8FD4586B-D78B-4979-AD18-0EB027B6B336</gtr:id><gtr:outcomeId>WnyFNiZSrs80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2005-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The trial looked to see whether chemotherapy could be given more intensively by using growth factor support. The hypothesis was that instensification would improve outcomes for patients with osteosarcoma. Patients were randomised to:
:: 6 cycles of MAP chemotherapy every 3 weeks
:: 6 cyclles of MAP every 2 weeks with growth factor support</gtr:description><gtr:id>6B9633B0-F020-494E-AA7F-B32729C69480</gtr:id><gtr:impact>No improvement in outcomes was demonstrated. 
Histological response to surgery was demonstrated to be prognostic but not predictive.
This led to alternatives being researched in EURAMOS.</gtr:impact><gtr:outcomeId>tHi1xrLTmf3</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>BO06</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=107</gtr:url><gtr:yearDevCompleted>2007</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Database prospectively collecting information on patients who have joined this international clinical trial</gtr:description><gtr:id>212ED684-C5C0-4B4E-A904-D393AABBC0C6</gtr:id><gtr:impact>ASCO presentation 2013
Papers 2014 to 2015 -- see publications</gtr:impact><gtr:outcomeId>88552AC1E95</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>EURAMOS-1 clinical trial database (EOI data)</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Collated data from our participating groups in EURAMOS-1</gtr:description><gtr:id>632B4835-348A-4725-A4E5-22E87F7D2910</gtr:id><gtr:impact>None yet; pending maturity</gtr:impact><gtr:outcomeId>QAbAcWv8egB</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>EURAMOS-1 Common Data Set (collated)</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The databases from the three MRC CTU-coordinated trials in osteosarcoma were standardised and combined to allow long-term, cross-trial follow-up</gtr:description><gtr:id>F460775E-4203-4A7F-84ED-E79871986A47</gtr:id><gtr:impact>Results have been shared at conferences. Three papers have recently been published (some on-line only, still).
A data release to an international collaboration (led from Australia) looking at prognostic factors in osteosarcoma was presented at ASCO 2012 and a paper accepted by JCO in Nov-2012</gtr:impact><gtr:outcomeId>D37835B22E9</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>BO02, BO03, BO06</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>52EE3F8C-571B-462F-B661-06977C35D4FF</gtr:id><gtr:title>Clinico-histologic parameters of osteosarcoma patients with late relapse.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0eb85606e7b9a087deb8e4c53d78d477"><gtr:id>0eb85606e7b9a087deb8e4c53d78d477</gtr:id><gtr:otherNames>Hauben EI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>9384EB47C03</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>000CD0A2-E1E0-4F13-AB10-10A86FB6EE16</gtr:id><gtr:title>Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71c69e1993b06d9c93ff1ae128a00f19"><gtr:id>71c69e1993b06d9c93ff1ae128a00f19</gtr:id><gtr:otherNames>McTiernan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>oq1xjhkVhpg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EADEBCF-4CBB-4EBF-949C-10864B7A6E81</gtr:id><gtr:title>Workshop report on the 2nd Joint ENCCA/EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology</gtr:title><gtr:parentPublicationTitle>Clinical Sarcoma Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d18fb1b7db6463f666cedb200d3e6aaa"><gtr:id>d18fb1b7db6463f666cedb200d3e6aaa</gtr:id><gtr:otherNames>Anninga J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5457bfc7e46f72.83932675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9975E80B-DB4D-4FC7-A66D-A5EE99896DC8</gtr:id><gtr:title>Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e572b74e8a05a698c389b24e77b3a6"><gtr:id>30e572b74e8a05a698c389b24e77b3a6</gtr:id><gtr:otherNames>Collins M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>pm_13787_27_23669227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF9BE38C-AEB7-4A37-865E-0D88602467E8</gtr:id><gtr:title>International collaboration is feasible in trials for rare conditions: the EURAMOS experience.</gtr:title><gtr:parentPublicationTitle>Cancer treatment and research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d2a1cfb59235e7ed66e67e2290b933e"><gtr:id>1d2a1cfb59235e7ed66e67e2290b933e</gtr:id><gtr:otherNames>Marina N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0927-3042</gtr:issn><gtr:outcomeId>dMQKGWbRDkB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CA5294F-E786-4A4D-B164-26872BC888FC</gtr:id><gtr:title>Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8a9b8e08753a466b4874512f5edd1ce"><gtr:id>f8a9b8e08753a466b4874512f5edd1ce</gtr:id><gtr:otherNames>Whelan JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>ra5eR49qwDh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88653B43-A7DE-4946-BB70-429979CC47CD</gtr:id><gtr:title>Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a77c229f955d5ddab38c54c5eda10bd"><gtr:id>9a77c229f955d5ddab38c54c5eda10bd</gtr:id><gtr:otherNames>Lewis IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>5C232925E05</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8740F97A-FE22-4FC0-8709-BA47A5E349DA</gtr:id><gtr:title>Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fee213606d4afb5ba8dc5008acb22915"><gtr:id>fee213606d4afb5ba8dc5008acb22915</gtr:id><gtr:otherNames>Gelderblom H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>dDqj4F6eGaC</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122861384</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>